Physician profile
Tara Mann
NPI 1639510837
$2,254.16
in general payments reported to CMS, 2019-2025
21 companies · $16.75 in 2025
The $16.75 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $417 · 2023: $1,063 · 2024: $758 · 2025: $16.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $395.84 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $296.25 | 2022-2024 | Verquvo |
| Pfizer INC. | $287.51 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $188.08 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $161.92 | 2022-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $159.07 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.02 | 2022-2024 | Jardiance |
| Amgen INC. | $98.50 | 2023-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $70.99 | 2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $60.49 | 2022-2023 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $57.83 | 2023 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $46.38 | 2022 | |
| Daiichi Sankyo INC. | $44.71 | 2024 | Injectafer |
| Medtronic, INC. | $39.99 | 2023 | Linq II |
| Boston Scientific Corporation | $39.34 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $37.55 | 2024 | |
| Abbott Laboratories | $34.70 | 2024 | Mitraclip |
| Alnylam Pharmaceuticals INC. | $29.00 | 2024 | Amvuttra |
| Baxter Healthcare | $26.93 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $17.31 | 2023 | Farxiga |
| Esperion Therapeutics, INC. | $16.75 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.